IMPACT OF DARATUMUMAB (DARA) ADMINISTRATION DURING TRANSPLANT- ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) INDUCTION ON STEM CELL (SC) MOBILIZATION COUNT AND POST-TRANSPLANT ENGRAFTMENT EQ Crusoe; A Moura; M Chaves; M Salvino; J Santos; H Santos; A Santos; L Lucas; J Leal; MG Arruda;

EFFECTS OF DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE (C), THALIDOMIDE (T) AND DEXAMETHASONE (D) COMBINATION ON LYMPHOCYTE POPULATIONS OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSE MULTIPLE MYELOMA PATIENTS A Santos; H Santos; J Santos; L Lucas; M Salvino; A Almeida; M Santos; A Torres; MG Arruda; EQ Crusoe;

REAL-WORLD DATA ON THE DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE MAINTENANCE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS EQ Crusoe; GN Ribeiro; FL Moura; AC Neto; M Aranha; RI Bittencourt; EF Ribeiro; JVP Neto; A Maiolino; V Hungria;